

LYMPHOID NEOPLASIA

CME Article

Genetic characterization of B-cell prolymphocytic leukemia: a prognostic model involving *MYC* and *TP53*

Elise Chapiro,^{1,3} Elodie Pramfil,^{1,2} M'boyba Diop,⁴ Damien Roos-Weil,^{1,2,5} Clémentine Dillard,^{1,2} Clémentine Gabillaud,³ Karim Maloum,³ Catherine Settegrana,³ Lucile Baseggio,⁶ Jean-François Lesesve,⁷ Mélanie Yon,^{1,2} Ludovic Jondreville,^{1,2} Claude Lesty,² Frédéric Davi,^{1,3} Magali Le Garff-Tavernier,^{1,3} Nathalie Droin,⁴ Philippe Dessen,⁴ Caroline Algrin,⁸ Véronique Leblond,^{2,5} Jean Gabarre,⁵ Simon Bouzy,³ Virginie Eclache,⁹ Baptiste Gaillard,¹⁰ Evelyne Callet-Bauchu,⁶ Marc Muller,¹¹ Christine Lefebvre,¹² Nathalie Nadal,¹³ Antoine Ittel,¹⁴ Stéphanie Struski,¹⁵ Marie-Agnès Collonge-Rame,¹⁶ Benoit Quilichini,¹⁷ Sandra Fert-Ferrer,¹⁸ Nathalie Auger,¹⁹ Isabelle Radford-Weiss,²⁰ Lena Wagner,²¹ Sebastian Scheinost,²¹ Thorsten Zenz,²² Santos A. Susin,^{1,2} Olivier A. Bernard,^{23,24} and Florence Nguyen-Khac,^{1,3} for the Groupe Francophone de Cytogénétique Hématologique (GFCH) and the French Innovative Leukemia Organization (FILO)

¹Cell Death and Drug Resistance in Lymphoproliferative Disorders Team, Centre de Recherche des Cordeliers, INSERM UMR 1138, Paris, France; ²Sorbonne Université, Paris, France; ³Service d'Hématologie Biologique, Hôpital Pitié-Salpêtrière, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France; ⁴AMMICA, INSERM US23/Centre National de la Recherche UMS3655, Gustave Roussy, Villejuif, France; ⁵Service d'Hématologie Clinique, Hôpital Pitié-Salpêtrière, AP-HP, Paris, France; ⁶Service d'Hématologie Biologique, hospices Civils de Lyon, Lyon, France; ⁷Service d'Hématologie Biologique, Centre Hospitalier Régionaux et Universitaire Nancy, and INSERM U1256 NGERE, Université de Lorraine, Nancy, France; ⁸Service d'Oncologie, Groupe Hospitalier Mutualiste de Grenoble, Grenoble, France; ⁹Laboratoire d'Hématologie, Hôpital Avicenne, AP-HP, Bobigny, France; ¹⁰Laboratoire d'Hématologie, Hôpital Robert Debré, Reims, France; ¹¹Laboratoire de Génétique, Centre Hospitalier Universitaire (CHU) Nancy, Nancy, France; ¹²Laboratoire de Cytogénétique Onco-hématologique, CHU Grenoble, Grenoble, France; ¹³Service de génétique chromosomique et moléculaire, CHU Dijon, Dijon, France; ¹⁴Cytogénétique, Institut Universitaire du Cancer de Toulouse, Toulouse, France; ¹⁵Laboratoire de Cytogénétique Hématologique, CHU Strasbourg, Strasbourg, France; ¹⁶Service de Génétique Biologique-Histologie, CHU Besançon, Besançon, France; ¹⁷Département Hématologie Cellulaire/Cytogénétique, Biomnis, Lyon, France; ¹⁸Laboratoire de Génétique Chromosomique, Centre Hospitalier Métropole Savoie, Chambéry, France; ¹⁹Laboratoire de Cytogénétique, Institut Gustave Roussy, Villejuif, France; ²⁰Laboratoire de Cytogénétique, Hôpital Necker-Enfants Malades, AP-HP, Paris, France; ²¹National Center for Tumor Diseases and German Cancer Research Centre, Heidelberg, Germany; ²²Department of Medical Oncology and Haematology, University Hospital Zurich and University of Zürich, Zürich, Switzerland; ²³INSERM, U1170, Institut Gustave Roussy, Villejuif, France; and ²⁴Université Paris-Sud/Paris Saclay, Orsay, France

KEY POINTS

- B-PLL is tightly linked to *MYC* aberrations (translocation or gain) and 17p (*TP53*) deletion.
- Cases of B-PLL with *MYC* aberration and 17p (*TP53*) deletion have the worst prognosis.

B-cell prolymphocytic leukemia (B-PLL) is a rare hematological disorder whose underlying oncogenic mechanisms are poorly understood. Our cytogenetic and molecular assessments of 34 patients with B-PLL revealed several disease-specific features and potential therapeutic targets. The karyotype was complex (≥ 3 abnormalities) in 73% of the patients and highly complex (≥ 5 abnormalities) in 45%. The most frequent chromosomal aberrations were translocations involving *MYC* [t(*MYC*)] (62%), deletion (del)17p (38%), trisomy (tri)18 (30%), del13q (29%), tri3 (24%), tri12 (24%), and del8p (23%). Twenty-six (76%) of the 34 patients exhibited an *MYC* aberration, resulting from mutually exclusive translocations or gains. Whole-exome sequencing revealed frequent mutations in *TP53*, *MYD88*, *BCOR*, *MYC*, *SF3B1*, *SETD2*, *CHD2*, *CXCR4*, and *BCLAF1*. The majority of B-PLL used the *IGHV3* or *IGHV4* subgroups (89%) and displayed significantly mutated *IGHV* genes (79%). We identified 3 distinct cytogenetic risk groups: low risk (no *MYC* aberration), intermediate risk (*MYC* aberration but no del17p), and high risk (*MYC* aberration and del17p) ($P = .0006$). In vitro drug response profiling revealed that the combination of a B-cell receptor or *BCL2* inhibitor with OTX015 (a bromodomain and extra-terminal motif inhibitor targeting *MYC*) was associated with significantly lower viability of B-PLL cells harboring a t(*MYC*). We concluded that cytogenetic analysis is a useful diagnostic and prognostic tool in B-PLL. Targeting *MYC* may be a useful treatment option in this disease. (*Blood*. 2019;134(21):1821-1831)



JOINTLY ACCREDITED PROVIDER™
INTERPROFESSIONAL CONTINUING EDUCATION

Medscape Continuing Medical Education online

In support of improving patient care, this activity has been planned and implemented by Medscape, LLC and the American Society of Hematology. Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Medscape, LLC designates this Journal-based CME activity for a maximum of 1.00 AMA PRA Category 1 Credit(s)[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

All other clinicians completing this activity will be issued a certificate of participation. To participate in this journal CME activity: (1) review the learning objectives and author disclosures; (2) study the education content; (3) take the post-test with a 75% minimum passing score and complete the evaluation at <http://www.medscape.org/journal/blood>; and (4) view/print certificate. For CME questions, see page 1879.

Disclosures

Associate Editor John C. Byrd received grants for clinical research from Acerta; Genentech, Inc.; Janssen Pharmaceuticals, Inc.; and Pharmacyclics, Inc. CME questions author Laurie Barclay, freelance writer and reviewer, Medscape, LLC and the authors declare no competing financial interests.

Learning objectives

Upon completion of this activity, participants will be able to:

1. Describe the genetic portrait of B-cell prolymphocytic leukemia (B-PLL), according to cytogenetic and molecular testing in a case series
2. Determine correlations between cytogenetic and molecular findings and patients' clinical outcomes, according to cytogenetic and molecular testing in a case series
3. Identify primary B-PLL cells' in vitro response to novel targeted therapeutics, according to cytogenetic and molecular testing in a case series

Release date: November 21, 2019; Expiration date: November 21, 2020

Introduction

B-cell prolymphocytic leukemia (B-PLL) is a very rare disease that accounts for <1% of all cases of chronic B-cell leukemia and generally occurs in elderly individuals. According to the World Health Organization criteria, B-PLL can be diagnosed when prolymphocytes comprise >55% of the lymphoid cells in peripheral blood. Diagnosis on the basis of clinical and morphological data can be difficult because B-PLL shares a number of features with other B-cell malignancies, including splenic marginal zone lymphoma (MZL), mantle cell lymphoma (MCL), and chronic lymphocytic leukemia (CLL). For example, an unusual leukemic form of MCL mimicking B-PLL is distinguished by the presence of the t(11;14)(q13;q32) translocation.^{1,2} B-PLL does not have a specific immunophenotype and has low Matutes scores,^{3,4} as observed for other B lymphoproliferative disorders.

Little is known about the oncogenic events leading to the development and clinical heterogeneity of B-PLL. Given the disease's rarity, its cytogenetic features have only been described in case reports and small series,^{5,6} and large-scale genomic sequencing has not yet been performed for this disease.

Rituximab-based chemo-immunotherapy is often used to treat patients who have B-PLL but no *TP53* aberrations. In patients with *TP53* aberrations, alemtuzumab-based regimens have been implemented. Lasting treatment responses are rare, and the prognosis is generally poor.⁷ Recent data from case reports and small series suggest that 2 agents targeting B-cell signaling (ibrutinib and idelalisib) are efficacious.⁸⁻¹⁰ Hence, allogeneic hematopoietic stem cell transplantation is still the only curative treatment of B-PLL, albeit in younger patients only.⁷

In the present study, we performed cytogenetic and molecular assessments in one of the largest reported series of patients with a validated diagnosis of B-PLL. We further sought correlations between the cytogenetic and molecular findings and the patients' clinical outcomes. Lastly, we studied the

in vitro response of the primary B-PLL cells to novel targeted therapeutic agents. To the best of our knowledge, the present study is the first to provide an extensive genetic portrait of B-PLL and to offer insights into prognostic markers and treatment options.

Patients, materials, and methods

Patient selection

Databases from 28 French health care establishments were retrospectively screened for cases of de novo B-PLL. Patients with a history of another B-cell malignancy (CLL or MZL) were excluded. A total of 87 patients with an available blood smear at diagnosis were first identified locally, based on cell morphological criteria. All 87 blood smears were blind-reviewed by 3 independent expert cytologists (L.B., K.M., and C.S.), and 10 representative smears were subsequently reviewed further by a fourth cytologist (J.-F.L.) (supplemental Methods; supplemental Table 1; available on the *Blood* Web site). Only 34 of the 87 cases met the World Health Organization criteria for B-PLL (ie, prolymphocytes accounted for >55% of the lymphoid cells in peripheral blood). A diagnosis of MCL was ruled out according to karyotype (K) and fluorescence in situ hybridization (FISH) assays: no *CCND1* rearrangements or other infrequent translocations involving *CCND2* and *CCND3* were observed.^{11,12} Four other patients carrying a translocation t(11;14)(q13;q32) with a *CCND1* rearrangement were diagnosed as having MCL and were excluded. Cytogenetic and molecular analyses were performed on the available material: at diagnosis for 21 patients, during follow-up and before treatment for 10 patients (median time between diagnosis and sampling, 44 months), and at relapse for 3 patients. The study was performed in accordance with the Declaration of Helsinki and was approved by the local investigational review board (CPP-Ile-de-France VI, Paris, France) on 21 May 2014.

Karyotyping and FISH analysis

Standard chromosome banding analyses were used to obtain R- or G-banded chromosomes from peripheral blood (n = 28),

bone marrow (n = 4), or spleen (n = 1) samples. The samples were cultured for 48 to 72 hours with 12-*O*-tetradecanoylphorbol-13-acetate (n = 6) or CpG-oligonucleotides and interleukin-2 (n = 27). All the karyotyping results were reviewed by the members of the Groupe Francophone de Cytogénétique Hématologique and classified according to the International System for Human Cytogenetic Nomenclature (2016). Complex Ks (CKs) and highly complex Ks (HCKs) were defined as the presence of at least 3 or 5 numerical or structural chromosomal abnormalities, respectively. Standard FISH was performed in all cases. The specific probes and procedures used are detailed in the supplemental Methods.

Whole-exome sequencing

DNA extracted from flow-sorted CD19⁺ tumor cells (and CD5⁺, IGL, or IGK when appropriate) and nontumor (CD3⁺) cells (considered to be germinal controls) was used for exome capture according to standard procedures. Paired-end sequencing was performed by using HiSeq2000 sequencing instruments (Illumina, San Diego, CA). More detailed information can be found in the supplemental Methods.

Targeted deep resequencing

Mutation validation using targeted deep resequencing was performed as previously described.¹³ Details are available in the supplemental Methods.

IGHV analysis

IGH rearrangement sequencing was performed on DNA extracted from sorted tumor cells or from whole blood, as previously described.¹⁴ Depending on the percentage of identity of the *IGHV* genes with their germline counterparts, sequences were considered as unmutated (100% identity), minimally/borderline mutated (99.9%-97%), or significantly mutated (<97% identity), following criteria proposed by Hadzidimitriou et al¹⁵ for MCL and Bikos et al¹⁶ for MZL.

RNA sequencing

RNA sequencing (RNA-seq) was performed on high-quality RNA from twelve B-PLL as previously described.¹⁷ More detailed information can be found in the supplemental Methods.

In vitro cell viability and programmed cell death assays

The viability of primary B-PLL cells was assessed with the adenosine triphosphate (ATP)-based CellTiter-Glo 2.0 assay (Promega, Madison, WI). Briefly, after pretreatment (or not) with the bromodomain and extra-terminal motif protein inhibitors (iBETs) OTX015 or JQ1 (500 nM), B-PLL cells were exposed for 48 hours to increasing concentrations of fludarabine, ibrutinib, idelalisib, or venetoclax. Viability was determined by normalizing luminescence units against a dimethyl sulfoxide control. Alternatively, programmed cell death was measured by flow cytometry using Annexin-V and propidium iodide colabeling, after B-PLL cell treatment of 48 hours with ibrutinib, idelalisib, venetoclax, or OTX015. Details are provided in the supplemental Methods. All drugs were purchased from Selleckchem (Houston, TX).

Statistical analysis

Overall survival (OS) was defined as the time interval between diagnosis and death or last follow-up. Categorical variables were

Table 1. Characteristics of the patients with B-PLL

Parameter	Whole cohort (N = 34)
Age at diagnosis, median (range), y	72 (46.2-87.9)
Sex, male/female	20/14
Splenomegaly, n/N (%)	18/31 (58)
Lymphadenopathy, n/N (%)	6/31 (19)
Lymphocytosis, median (range), G/L	36 (4.6-244)
Prolymphocytes, median (range), %	79.5 (60-100)
Treated patients, n/N (%)	29/33 (88)
Death, n/N (%)	14/33 (42)
Follow-up, median (range), mo	47 (0.2-141)
OS, median (95% CI), mo	125.7 (52.3-132.1)
TTT, median (95% CI), mo	5.8 (1.5-27.5)
CD38 ⁺ , n/N (%)	20/33 (61)
Matutes score, n/N (%)	
0	8/33 (25)
1	11/33 (33)
2	9/33 (27)
3	5/33 (15)
CD5 ⁺ , n/N (%)	19/34 (56)
CD23 ⁺ , n/N (%)	11/34 (32)
CK (≥3 abnormalities)*, n/N (%)	24/33 (73)
HCK (≥5 abnormalities)*, n/N (%)	15/33 (45)
No. of karyotypic aberrations, median (range)*	4 (1-21)
Unbalanced translocations*, n/N (%)	23/33 (70)
t(MYC), n/N (%)	21/34 (62)
del17p (TP53), n/N (%)	13/34 (38)
tri12, n/N (%)	8/34 (24)
tri3, n/N (%)	8/33 (24)
tri18, n/N (%)	10/33 (30)
MYC gain, n/N (%)	5/34 (15)
del13q, n/N (%)	10/34 (29)
del8p (TNFRSF10), n/N (%)	7/31 (23)
<i>IGHV</i> mutated, n/N (%)	16/19 (84)
<i>TP53</i> mutated, n/N (%)	6/16 (38)
<i>MYD88</i> mutated, n/N (%)	4/16 (25)
<i>BCOR</i> mutated, n/N (%)	4/16 (25)
<i>MYC</i> mutated, n/N (%)	3/16 (19)
<i>SF3B1</i> mutated, n/N (%)	3/16 (19)

CI, confidence interval; TTT, time to first treatment.

*The frequency of chromosomal abnormalities did not differ significantly when comparing patients at diagnosis vs patients during follow-up and treated patients vs untreated patients.




Figure 1. Distribution of chromosomal abnormalities detected in 34 patients with B-PLL with 3 cytogenetic subgroups of patients: MYC translocation, MYC gain, and no MYC aberration. Each column represents 1 patient, and each row 1 particular genetic or laboratory parameter. Color code: black or blue, presence; gray, absence; white, not available. CK, ≥ 3 chromosomal abnormalities; HCK, ≥ 5 chromosomal abnormalities. The percentages of polymphocytes (indicated in black boxes) correspond to above-median values, relative to the cohort as a whole.

compared by using a χ^2 test or Fisher's exact test; continuous variables were compared by using the Mann-Whitney *U* test. Survival analyses were performed by using the Kaplan-Meier method, and the log-rank test was used for intergroup comparisons of OS curves. Two-sided *P* < .05 was considered statistically significant. All statistical analyses were performed by using MedCalc software (version 17.8.6, Ostend, Belgium).

Additional methods are described in the supplemental Methods.

Results

Characteristics of the study population

The study included 34 patients diagnosed with de novo B-PLL between 1992 and 2017 (Table 1). There was a predominance of male subjects (59%), and the median (range) age at diagnosis was 72 (46.2-87.9) years. The median lymphocyte count was 36 (4.6-244) G/L, and the median proportion of polymphocytes was 79.5 (60-100). Nineteen of the 34 patients (56%) were positive for CD5 (supplemental Table 2). The median follow-up time after diagnosis was 47 (0.2-141) months. Most of the patients had been treated (29 of 33 [88%]) with a median time after diagnosis of 3.2 (0-106) months.

Chromosomal aberrations: MYC is the most frequently altered gene in B-PLL

Karyotyping was performed in 33 patients (Table 1; supplemental Table 3). A CK was found in 73% of the patients, and HCK in 45%. By combining K and FISH data, we observed that the most frequent abnormality, found in 21 (62%) of the 34 patients, was a translocation involving the *MYC* gene [t(*MYC*)]. This translocation involved the *IGH* locus in 12 cases, *IGL* in 6, and *IGK* in 1; the *MYC* gene partner was not identified in 2 cases. Five

(15%) of the 34 patients had gained copies of the *MYC* gene: three had 3 copies, one had 4 copies, and one had *MYC* amplification. Thus, the majority of the cases (26 of 34 [76%]) had an *MYC* abnormality, *MYC* translocation and *MYC* gain being mutually exclusive. The other frequent chromosomal aberrations were: deletion (del)17p including the *TP53* gene (13 of 34 [38%]), trisomy (tri) 18/18q (10 of 33 [30%]), del13q (10 of 34 [29%]), tri3 (8 of 33 [24%]), tri12 (8 of 34 [24%]), and del8p (7 of 31 [23%]) (Figure 1).

An analysis of copy number values (calculated from the whole-exome sequencing [WES] coverage in 16 patients) confirmed the majority of recurrent losses and gains observed by karyotyping and/or FISH analyses and highlighted other novel recurrent copy number variations: losses of 5q22-23, 9q34, 14q24, and 19p13, and gains of 17q24, 1q31-42, and 4q27-35 (supplemental Table 4).

IGHV analyses: preferential usage of VH3 and VH4 genes, and frequently mutated IGHV genes

We obtained clonal *IGH* sequences in 19 patients with B-PLL. In 17 (89%) of the 19 B-PLL cases, a member of the *IGHV3* (*n* = 11, including 4 *IGHV3-23*) or *IGHV4* (*n* = 6) subgroups was involved; the *IGHV1* subgroup gene (*IGHV1-2*) was used in the 2 remaining cases. Furthermore, the vast majority of B-PLL sequences (15 of 19 [79%]) displayed significantly mutated *IGHV* genes (Figure 1; supplemental Table 5).

The spectrum of somatic mutations

WES of paired tumor-control DNA was performed in 16 patients, and mutations were validated by using targeted deep-resequencing and/or RNA-seq (supplemental Figure 1; supplemental Table 6). We identified 10 genes that were mutated in at least 2 patients

Table 2. Recurrently mutated genes identified by using WES in 16 patients with B-PLL

Gene	No. of cases	No. of mutations identified	Mutations	Biological process
<i>TP53</i> (NM_000546)	6	7	p.A129Pfs*41 + p.V132L, T205C, V236G, A248D, L275Q, R282P	Cell cycle, apoptosis
<i>MYD88</i> (NM_002468)	4	4	L265Pfs*2, M232T, S219C	NF- κ B pathway
<i>BCOR</i> (NM_001123385)	4	4	F924C, N1459Sx2, P1648Lfs*4	Chromatin remodeling
<i>MYC</i> (NM_002467)	3	3	V160L, S161L, F389L	Cell cycle
<i>SF3B1</i> (NM_012433)	3	3	K700Ex3	Spliceosome
<i>SETD2</i> (NM_014159)	2	2	2 p.Gly878Glnfs*14, L1577P	Chromatin remodeling (histone H3K36 methyltransferase)
<i>CHD2</i> (NM_001271)	2	2	P1387Rfs*13, V1163Gfs*3	Chromatin remodeling
<i>CXCR4</i> (NM_003467)	2	2	S338X, S325Qfs*22	Cell migration
<i>BCLAF1</i> (NM_001077440)	2	2	R820C, W211X	RNA processing factor
<i>NFASC</i> (NM_001005388)	2	2	T946I, V644M	Neuronal development

(Table 2). The most frequently mutated gene was *TP53*, with a total of 7 mutations observed in 6 (38%) of the 16 patients. These *TP53* mutations were predicted to affect the protein's DNA-binding domain (supplemental Figure 2). In all cases, these mutations were associated with a del17p. Mutations in *MYD88* were found in 4 patients. Interestingly, the *MYD88* mutation was associated with tri3 in 2 cases, with a variant allele frequency of 66.5% (BPLL_6) and 67.4% (BPLL_32) indicating that

the mutated copy was duplicated. Mutations in genes that have a role in chromatin modifications were recurrent, including the X-linked *BCOR* gene encoding a BCL6 corepressor ($n = 4$), *CHD2* ($n = 2$), *SETD2* ($n = 2$), and other genes mutated in 1 patient each (*CREBBP*, *EZH2*, *KMT2D*, *NCOR1*, *SETD1B*, and *TET2*). The *MYC* gene had missense mutations in 3 patients, all of whom harbored a t(*MYC*). Two mutations were just downstream of the transactivation domain, and one was in the bHLH




Figure 2. WES and RNA-seq. (A) Distribution of the chromosomal aberrations and mutations in the 3 cytogenetic subgroups (*MYC* translocation, *MYC* gain, and no *MYC* aberration) in the 16 cases analyzed by using WES. Chromosomal abnormalities: gray, absence; color, presence. Mutations: gray, wild type; color, mutated. (B) Principal component analysis of differential gene expression patterns for 12 samples with various cytogenetic abnormalities.

Table 3. Comparison of the 3 cytogenetic subgroups (S) (MYC translocation, MYC gain, and no MYC activation): significant results

Parameter	S1: t(MYC) (n = 21 [62%])	S2: MYC gain (n = 5 [15%])	S3: no MYC (n = 8 [23%])	Comparison	P
Polymphocytes (range), %	86 (61-100)	79 (66-91)	76 (60-80)	S1 vs S2 + S3	.03
				S3 vs S1 + S2	.03
CD38 ⁺ , n/N (%)	18/20 (90)	2/5 (40)	0/8 (0)	S1 vs S2 + S3	<.0001
				S3 vs S1 + S2	<.001
No. of chromosomal abnormalities (range)	3 (1-9)	6 (5-21)	10 (1-15)	S1 vs S2 + S3	.0005
				S3 vs S1 + S2	.02
HCK (≥5 abnormalities), n/N (%)	4/20 (20)	5/5 (100)	6/8 (75)	S1 vs S2 + S3	.0004
				S2 vs S1 + S3	.01
Unbalanced translocations, n/N (%)	11/20 (55)	5/5 (100)	7/8 (88)	S1 vs S2 + S3	.04
del17p, n/N (%)	3/21 (14)	4/5 (80)	6/8 (75)	S1 vs S2 + S3	.0006
				S3 vs S1 + S2	.03
tri3, n/N (%)	4/20 (20)	4/5 (80)	0/8 (0)	S2 vs S1 + S3	.008

domain. The products of other relevant mutated genes were found to be involved in RNA metabolism (*SF3B1*, *BCLAF1*, *ZRSR2*, and *WBP4*), cell migration (*CXCR4*), cell cycle (*CDKN3* and *RB1*), apoptosis (*TP73*), and NOTCH signaling (*NOTCH2* and *FBXW7*) (Figure 2).

IGL/PVT1 fusions

Using RNA-seq, we detected *IG* fusion transcripts in 3 of 7 patients with t(MYC). In case #27 harboring a t(8;14)(q24;q32), *IGHG1* was fused with intron 1 of *MYC*. In cases BPLL_4 and BPLL_30 with a t(8;22)(q24;q11), the *PVT1* gene was fused to *IGLL5* or *IGLV4-69*01*, respectively. The 2 latter fusions were confirmed by using a reverse-transcriptase polymerase chain reaction assay. No other recurrent fusion transcripts were found in the 12 patients with RNA-seq data (supplemental Table 7).

Clonal organization

With a view to identifying early and late oncogenic events, we evaluated the clonal or subclonal nature of chromosomal abnormalities and recurrent somatic mutations. We observed that t(MYC), del17p, tri12, and mutations in the *TP53*, *BCOR*, *MYC*, *SF3B1*, and *MYD88* genes were mostly clonal and should be considered as early events in B-PLL. In contrast, *MYC* gain, del8p, and del13q were frequently subclonal, indicating that they are acquired (supplemental Figure 3).

Correlations between cytogenetic aberrations, mutations, and gene expression patterns

Three cytogenetic subgroups were identified (Figure 1; Table 3). The main subgroup of patients (21 of 34 [62%]) had a t(MYC). Relative to the patients without t(MYC), this subgroup had a higher percentage of polymphocytes ($P = .03$), a higher proportion of CD38⁺ cells ($P < .0001$), a lower level of cytogenetic complexity ($P = .0005$), a lower proportion of cases with HCK ($P = .0004$), fewer unbalanced translocations ($P = .04$), and fewer cases with del17p ($P = .0006$). Mutations in

MYC and in genes involved in RNA metabolism, chromatin remodeling and transcription were almost exclusively observed in the t(MYC) subgroup, whereas mutations in *TP53* were less frequent (Figure 2A). A principal component analysis of gene expression data from the 12 cases analyzed by using RNA-seq showed that the 7 patients with t(MYC) clustered together (Figure 2B). Taken as a whole, these results suggest that patients with t(MYC) form a homogeneous subgroup of B-PLL. A second subgroup of B-PLL with *MYC* gain (5 of 34 [15%]) was associated with HCK ($P = .01$) and tri3 ($P = .008$). The remaining 8 patients corresponded to a third subgroup lacking an *MYC* aberration. Compared with patients with the *MYC* aberration, this third subgroup had a lower percentage of polymphocytes ($P = .03$), no CD38⁺ expression ($P < .001$), a higher number of chromosomal aberrations ($P = .02$), and a higher frequency of del17p ($P = .03$) (Table 3).

Survival analyses: the prognostic values of MYC aberrations and del17p

The median OS for the entire study cohort was 125.7 months. Patients with t(MYC) had a median (95% CI) OS of 57.5 months (25.7-132.1), which did not differ significantly from the value observed for patients with *MYC* gain (median, 66.5 months) (Figure 3A). Hence, we pooled patients with an *MYC* aberration for subsequent OS comparisons and found that they had a significantly shorter OS than patients without *MYC* aberrations ($P = .03$) (Figure 3B).

With regard to the combination of *MYC* and del17p aberrations, 3 distinct prognostic groups were identified with significant differences in OS ($P = .0006$) (Figure 3C). The patients without an *MYC* aberration ($n = 8$) had the lower risk (median not reached). Patients with an *MYC* aberration (translocation or gain) but no del17p ($n = 18$) had an intermediate risk (125.7 months). The high-risk group corresponded to patients with both *MYC* and del17p ($n = 7$; 11.1 months).




Figure 3. Overall survival in patients with B-PLL. Panels A-B as a function of *MYC* aberrations [t(*MYC*) or gain] and the presence or absence of *MYC* aberration; the t(*MYC*) and *MYC* gain data were pooled. (A) t(*MYC*) median (95% CI), 57.5 months (25.7-132.1); *MYC* gain median (95% CI), 66.5 months (4.7-undetermined). (B) *MYC* aberration [t(*MYC*) + *MYC* gain] median (95% CI), 57.5 (25.7-132.1). (C) *MYC* and del17p status. *MYC* aberration without del17p median (95% CI), 125.7 months (52.2-132.1); *MYC* aberration with del17p median (95% CI), 11.1 months (4.7-66.5). ab, aberration.

Other chromosomal abnormalities and K complexity had no significant impact on OS. Patients with del17p tended to have a shorter OS than those without del17p (supplemental Figure S4).

In vitro drug response assays

To evaluate the sensitivity of B-PLL cells to drugs used in the treatment of B-cell malignancies, we first used a cell viability assay based on the quantification of cellular ATP levels (an

indicator of metabolic activity¹⁸) on primary B-PLL cells after 48 hours of exposure to ibrutinib, idelalisib (both B-cell receptor inhibitors), venetoclax (a highly specific inhibitor of the antiapoptotic protein BCL2), and fludarabine. The drugs were tested alone or in combination with OTX015 (an iBET known to suppress *MYC* expression in leukemia and lymphoma cell lines).¹⁹⁻²¹ Treatment with increasing doses of single drugs resulted in reduced cell viability in the 3 cases with t(*MYC*) (BPLL_8, BPLL_13, and BPLL_18) but varied from one drug to another and from one patient to another. Relative to treatments with single drugs, OTX015 cotreatment with low doses of fludarabine, ibrutinib, or venetoclax was associated with a much lower level of viability (<30%) in patients with t(*MYC*) (Figure 4A). In contrast, the patient harboring a del17p but not an *MYC* aberration (BPLL_34) was significantly more resistant to single drugs and OTX015 cotreatments than patients with t(*MYC*) (Figure 4B).

To confirm these results, a complementary cytofluorometric approach was used. In BPLL_8 with t(*MYC*), treatments with drugs alone killed between 13% and 27% of the cells. An additive effect of OTX015 was observed; between 48% and 63% of the cells were killed (Figure 4C). Cells from patient BPLL_34 (del17p but no *MYC* aberration) were less sensitive to all drugs tested in both the presence and absence of OTX015 (Figure 4D). Thus, the ATP assay and flow cytometry assay results highlighted the efficacy of combined drug + iBET treatment of cells from patients with t(*MYC*). The enhancing effect of the iBETs on the programmed cell death induced by fludarabine, ibrutinib, and venetoclax was fully corroborated by the results of cotreatment with JQ1, another well-known iBET (supplemental Figure 5B-C). It should be noted that we did not test any cases with *MYC* gain.

Discussion

In the present study, 34 patients with B-PLL were genetically characterized. Given that the diagnosis of B-PLL is challenging, a thorough morphological review of blood smears was performed by 3 independent cytologists. Although patients with a history of MZL were excluded, the absence of a biopsy analysis means that we cannot fully rule out the possible presence of MZL with a prolymphocytoid transformation, an extremely rare situation.²²

To the best of our knowledge, the present series is the largest yet to have undergone a comprehensive genomic characterization of B-PLL. We found that the most frequent aberrations are related to *MYC* alterations (in 76% of cases), highlighting the major role of *MYC* in the pathogenesis of B-PLL. Strikingly, *MYC* translocations and *MYC* gain were found to be mutually exclusive. Translocations in which the *MYC* gene is repositioned under the control of an enhancer (usually immunoglobulin gene enhancers) result in the overexpression of *MYC*, as does the gain of one or more copies of *MYC*.²³ Although *MYC* translocations and mutations are classically associated with Burkitt lymphoma (BL), aberrations in *MYC* have also been linked to almost all B-cell neoplasms. With regard to B-PLL, *MYC* translocations and *MYC* gain have been reported in a few cases.²⁴⁻²⁹ In the present series, t(*MYC*) was present in the major clone, but *MYC* gain was mainly subclonal and/or overlooked as part of a CK. Thus, performing FISH with a specific probe is




Figure 4. The combination of drugs frequently used to treat B-cell malignancies with iBETs enhances the killing of primary B-PLL cells with t(MYC). (A) B-PLL cells from 3 patients with t(MYC) were treated with the indicated concentrations of ibrutinib, idelalisib, venetoclax, or fludarabine in the presence or absence of OTX015 (500 nM). Viability was assessed with an ATP-based CellTiter-Glo 2.0 kit. (B) B-PLL cell viability was measured and analyzed as in panel A in a patient with del17p but no MYC aberration. (C) Cell death was quantified in primary B-PLL cells from patient BPLL_8 [with t(MYC)] with or without pretreatment with OTX015 (500 nM) and exposure for 48 hours to ibrutinib (7.5 μM), idelalisib (50 μM), or venetoclax (10 nM). The percentages refer to Annexin-V–positive or Annexin-V–/propidium iodide–positive cells. (D) Primary B-PLL cells from BPLL_34 (with del17p but no MYC aberration) were treated with drugs and analyzed as in panel C. Bars represent the mean \pm SEM.

essential to identify *MYC* gain or amplification. *MYC* gene mutations were found in 3 cases, all of which also had *t(MYC)*. These mutations were not located in the transactivation domain (the hot spot for *MYC* mutations in BL). However, it is likely that *MYC* mutations have a role in the pathophysiology of B-PLL (as they do in BL) by enhancing the oncogenicity of *Myc*.³⁰ We found a fusion transcript between *PVT1* and an *IGL* gene in 2 patients with a variant *MYC* translocation *t(8;22)*. This fusion subsequently disrupted the *PVT1* gene, a long intergenic noncoding RNA located 55 kb downstream of *MYC* and which has been identified as a recurrent breakpoint in BL harboring variant translocations *t(2;8)* or *t(8;22)*.^{31,32} In a recent study, the *PVT1* promoter was found to behave like a tumor-suppressor DNA element: silencing the *PVT1* promoter increased *MYC* transcription and cell proliferation.³³ As with *MYC* mutations, disruption of the *PVT1* gene in some patients with B-PLL might cooperate functionally with translocations to increase *MYC*-mediated oncogenesis.

Our present results confirmed previous case reports in which a CK was frequent in B-PLL.^{24,27,34} The frequency of a CK in B-PLL (73% in the present study) is higher than that reported in BL (34%),³⁵ MCL (40%-60%),^{36,37} MZL (53%),³⁸ and CLL at diagnosis (15%)³⁹⁻⁴² and is similar to that observed in high-risk CLL.⁴³ Whereas *t(MYC)* is the main abnormality in B-PLL (62%), it is rare in other chronic B-cell disorders (ie, <5% in MCL, MZL, and CLL).^{28,38,44} The frequency of *del17p* in B-PLL (38%) observed here is higher than for MCL and MZL (both ~20%)^{37,38} or for CLL (5%-7% at diagnosis).^{39,45} In addition to *MYC* and *TP53* abnormalities, several other recurrent chromosomal aberrations were found in B-PLL, including trisomies 3, 12, and 18, *del13q*, and *del8p*. None of the chromosomal abnormalities observed in B-PLL are specific and thus can be observed in other mature B-cell malignancies, albeit at different frequencies. Similarly, all the driver genes recurrently mutated in B-PLL are also involved in other chronic B-cell disorders but not with the same prevalence. In line with previous studies,^{5,6} we found a high frequency of *TP53* mutations (38%) in B-PLL; this frequency is higher than that observed for other B-cell malignancies such as MCL (18%),⁴⁶ LYM (14%),⁴⁷ CLL (10%),⁴⁸ and BL (24%).⁴⁹

We identified a high frequency of clonal *BCOR* mutations, which were present only in *t(MYC)* patients. *BCOR* encodes a Bcl6 co-repressor that silences *BCL6* targets by epigenetic modifications.⁵⁰ Inactivating mutations of *BCOR* have been found in myeloid disorders^{51,52} but are very unusual in B-cell diseases, except in the rare splenic diffuse red pulp lymphoma.⁵³ The association of *BCOR* mutations and *t(MYC)* might be a specific feature of B-PLL. Indeed, a recent study of $E\mu$ -*Myc* lymphomas in a mouse model revealed a high frequency of *Bcor* mutations and showed that *Bcor* was a cooperative tumor suppressor gene, the disruption of which can accelerate *Myc*-driven lymphomagenesis.⁵⁴

Our data showed that patients with B-PLL and *t(MYC)* form a homogeneous subgroup, with a less K complexity, a higher proportion of prolymphocytes, and a higher frequency of CD38 expression. Interestingly, clonal mutations in the *MYC*, *BCOR*, and *SF3B1* genes clustered together in some patients with *t(MYC)*, suggesting oncogenic cooperation in the development of B-PLL. *MYC* aberration is a feature shared with BL; however, in contrast to BL, no mutation was found in *TCF3*, *ID3*, or *CCND3* genes in B-PLL.⁴⁹

van der Velden et al⁵⁵ have suggested that B-PLL is a specific subgroup of *t(11;14)*-negative MCL, based on similarities in the immunophenotype, immunogenotype, and gene expression profile. We did not find any *CCND1* or *ATM* mutations (the most frequent mutations in MCL⁵⁶) in our patients with B-PLL. The vast majority of B-PLL expressed significantly mutated *IGHV* genes belonging to the *IGHV3* and *IGHV4* subgroups, in keeping with previous reports.^{57,58} This finding contrasts with that of MCL, which exhibits predominantly no or minimal somatic hypermutations.¹⁵

Taken as a whole, our data show that the genomic profile of B-PLL shares similarities with that of chronic B-cell malignancies but also displays unique combinations of alterations, thus confirming that B-PLL is a distinct entity.

The median OS time in the study cohort was 125.7 months, longer than the times reported in 2 earlier studies.^{6,59} This difference might be due to our patients' treatments with rituximab, alemtuzumab, or fludarabine, all of which are reportedly efficacious in B-PLL.^{60,61} In light of our results, we propose a hierarchical prognostic model that depends on *MYC* aberration (translocation or gain) and *del17p*. Patients without an *MYC* aberration have indolent disease (regardless of their *17p* status), whereas patients with an *MYC* aberration have a significantly shorter OS time. A combination of *MYC* aberration and *del17p* confers the worse outcome, with a median OS of <1 year. By analogy with the "double-hit" form of CLL involving *del17p* and *MYC* gain,⁴³ these patients may be considered as having a very-high-risk form of B-PLL. Due to the rarity of this disease, our data were obtained with a relatively small number of patients and thus need to be confirmed in future studies.

Our *in vitro* data showed that a combination of ibrutinib, idelalisib, or venetoclax with OTX015 is more cytotoxic than the drugs used alone, especially in patients with *MYC* translocation. This scenario is concordant with the known effects of OTX015, an inhibitor of the bromodomain-containing proteins BRD2, BRD3, and BRD4. These proteins act as epigenetic readers and have an important role in the regulation of transcription and the modulation of oncogene expression. As with other iBETs, OTX015 strongly downregulates the transcription of genes regulated by super-enhancers such as *MYC*.²⁰ Current approaches to the treatment of B-PLL (as with CLL) are based on *del17p*. However, our results strongly suggest that *MYC* should be taken into account and could be targeted. OTX015 is already in phase 1 clinical studies with a relatively good safety profile⁶²; when combined with targeted drugs, it might constitute an epigenetic treatment option in patients with B-PLL and *MYC* translocation. In any case, further investigations with a larger number of patients (especially those with *MYC* gain) are required to make progress in this field.

In conclusion, we found that patients with B-PLL have CKs and HCKs, a high frequency of *MYC* aberration (by translocation or gain), frequent *del17p*, and frequent mutations in the *TP53*, *BCOR*, *MYD88*, and *MYC* genes. We identified 3 prognostic subgroups, depending on *MYC* and *17p* status. Patients with both *MYC* aberration and *del17p* had the shortest OS and should be considered as a high-risk subgroup. These results showed that cytogenetic analysis is a useful diagnostic and prognostic tool in B-PLL. We recommend karyotyping and FISH (for *MYC* and *TP53*) analyses whenever B-PLL is suspected. Moreover, these *in vitro* data strongly

suggest that drugs targeting the BCR and BCL2 in combination with an iBET might be a treatment option for patients with B-PLL.

Acknowledgments

The authors thank Hélène Merle-Béral for fruitful discussions; Remi Brissiaud, Philippe Rameau, Marie-Claire Grison, Laurent Merlin, Myriam Boudjoghra, Claire Quiney, and Marc Le Lorch for technical assistance; Nadia Bougacha for preliminary assessments; and Stéphanie Mathis, Chantal Brouze, Justine Siavellis, Catherine Godon, Pierre Lemaire, Xavier Troussard, Valérie Bardet, Eric Jeandidier, Dominique Penther, Jean-Baptiste Gaillard, Vincent Leymarie, Annie Brion, Catherine Thieblemont, Cécile Tomowiak, David Ghez, Jean-Marc Zini, and Kamel Laribi for their contribution in the patient selection, the Groupe Francophone d'Hématologie Cellulaire.

This project was funded by the Institut Thématique Multi-Organisme Cancer, the Institut National du Cancer, GEFLUC, Association Laurette Fugain (ALF 14/08), and Roche Diagnostics. E.P. and L.J. received fellowships from the French Research Ministry and Société Française d'Hématologie and Fondation ARC, respectively. This project is part of the International Cancer Genome Consortium program. This work was supported by CURAMUS (Cancer United Research Associating Medicine, University and Society; INCA-DGOS-Inserm_12560).

Authorship

Contribution: F.N.-K., O.A.B, S.A.S., and E.C. designed the study; E.C., E.P., M.D., D.R.-W., C.D., C.G., M.Y., L.J., C.L., F.D., M.L.G.-T., N.D., P.D., S.B., L.W., and S. Scheinost performed experiments and analyzed data; K.M., C.S., L.B., and J.-F.L. performed the morphological review; C.A., V.L., J.G., V.E., B.G., E.C.-B., M.M., C.L., N.N., A.I., S. Struski, M.-A.C.-R., B.Q., S.F.-F., N.A., and I.R.-W. provided samples and clinical data; and E.C., F.D., T.Z., S.A.S., O.A.B. and F.N.-K. wrote the manuscript.

Conflict-of-interest disclosure: The authors declare no competing financial interests.

A complete list of the members of the Groupe Francophone de Cytogénétique Hématologique (GFCH) and the French Innovative Leukemia Organization (FILO) appears in the supplemental appendix.

ORCID profiles: E.C., 0000-0003-3427-7596; D.R.-W., 0000-0002-7767-755X; K.M., 0000-0001-8864-4801; L.B., 0000-0001-7543-6480; F.D., 0000-0002-3764-063X; M.L.G.-T., 0000-0002-3131-3240; S.A.S., 0000-0002-3366-1628; F.N.-K., 0000-0003-3107-6668.

Correspondence: Florence Nguyen-Khac, Service d'Hématologie Biologique, Bâtiment Pharmacie, Pitié-Salpêtrière/Charles Foix University Hospital, 83 Bd de l'Hôpital, F-75013 Paris, France; e-mail: florence.nguyen-khac@aphp.fr.

Footnotes

Submitted 17 April 2019; accepted 12 August 2019. Prepublished online as *Blood* First Edition paper, 16 September 2019; DOI 10.1182/blood.2019001187.

The WES and RNA-seq data have been deposited in the European Genome-phenome Archive database (accession numbers EGAD00001002323, EGAD00001002438, and EGAD00001002476).

The online version of this article contains a data supplement.

There is a *Blood* Commentary on this article in this issue.

The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 USC section 1734.

REFERENCES

- Ruchlemer R, Parry-Jones N, Brito-Babapulle V, et al. B-prolymphocytic leukaemia with t(11;14) revisited: a splenomegalic form of mantle cell lymphoma evolving with leukaemia. *Br J Haematol*. 2004;125(3):330-336.
- Swerdlow SH, Campo E, Harris NL, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Revised 4th Edition. Lyon, France: International Agency for Research on Cancer; 2017.
- Matutes E, Owusu-Ankomah K, Morilla R, et al. The immunological profile of B-cell disorders and proposal of a scoring system for the diagnosis of CLL. *Leukemia*. 1994;8(10):1640-1645.
- Moreau EJ, Matutes E, A'Hern RP, et al. Improvement of the chronic lymphocytic leukemia scoring system with the monoclonal antibody SN8 (CD79b). *Am J Clin Pathol*. 1997;108(4):378-382.
- Lens D, De Schouwer PJ, Hamoudi RA, et al. p53 abnormalities in B-cell prolymphocytic leukemia. *Blood*. 1997;89(6):2015-2023.
- Hercher C, Robain M, Davi F, et al; Groupe Français d'Hématologie Cellulaire. A multicentric study of 41 cases of B-prolymphocytic leukemia: two evolutive forms. *Leuk Lymphoma*. 2001;42(5):981-987.
- Dearden C. How I treat prolymphocytic leukemia. *Blood*. 2012;120(3):538-551.
- Gordon MJ, Raess PW, Young K, Spurgeon SEF, Danilov AV. Ibrutinib is an effective treatment for B-cell prolymphocytic leukaemia. *Br J Haematol*. 2017;179(3):501-503.
- Eyre TA, Fox CP, Boden A, et al. Idelalisib-rituximab induces durable remissions in TP53 disrupted B-PLL but results in significant toxicity: updated results of the UK-wide compassionate use programme. *Br J Haematol*. 2019;184(4):667-671.
- Damlaj M, Al Balwi M, Al Mugairi AM. Ibrutinib therapy is effective in B-cell prolymphocytic leukemia exhibiting MYC aberrations. *Leuk Lymphoma*. 2018;59(3):739-742.
- Wlodarska I, Dierickx D, Vanhentenrijk V, et al. Translocations targeting CCND2, CCND3, and MYCN do occur in t(11;14)-negative mantle cell lymphomas. *Blood*. 2008;111(12):5683-5690.
- Salaverria I, Royo C, Carvajal-Cuenca A, et al. CCND2 rearrangements are the most frequent genetic events in cyclin D1(-) mantle cell lymphoma. *Blood*. 2013;121(8):1394-1402.
- Cosson A, Chapiro E, Belhouachi N, et al; Groupe Francophone de Cytogénétique Hématologique. 14q deletions are associated with trisomy 12, NOTCH1 mutations and unmutated IGHV genes in chronic lymphocytic leukemia and small lymphocytic lymphoma. *Genes Chromosomes Cancer*. 2014;53(8):657-666.
- Ghia P, Stamatopoulos K, Belessi C, et al; European Research Initiative on CLL. ERIC recommendations on IGHV gene mutational status analysis in chronic lymphocytic leukemia. *Leukemia*. 2007;21(1):1-3.
- Hadzidimitriou A, Agathangelidis A, Darzentas N, et al. Is there a role for antigen selection in mantle cell lymphoma? Immunogenetic support from a series of 807 cases. *Blood*. 2011;118(11):3088-3095.
- Bikos V, Darzentas N, Hadzidimitriou A, et al. Over 30% of patients with splenic marginal zone lymphoma express the same immunoglobulin heavy variable gene: ontogenetic implications. *Leukemia*. 2012;26(7):1638-1646.
- Merlevede J, Droin N, Qin T, et al. Mutation allele burden remains unchanged in chronic myelomonocytic leukaemia responding to hypomethylating agents. *Nat Commun*. 2016;7(1):10767.
- Dietrich S, Oleś M, Lu J, et al. Drug-perturbation-based stratification of blood cancer. *J Clin Invest*. 2018;128(11):427-445.
- Mertz JA, Conery AR, Bryant BM, et al. Targeting MYC dependence in cancer by inhibiting BET bromodomains. *Proc Natl Acad Sci U S A*. 2011;108(40):16669-16674.
- Chapuy B, McKeown MR, Lin CY, et al. Discovery and characterization of super-enhancer-associated dependencies in diffuse large B cell lymphoma [published correction appears in *Cancer Cell*. 2014;25(4):545-546]. *Cancer Cell*. 2013;24(6):777-790.
- Boi M, Gaudio E, Bonetti P, et al. The BET bromodomain inhibitor OTX015 affects pathogenetic pathways in preclinical B-cell tumor models and synergizes with targeted drugs. *Clin Cancer Res*. 2015;21(7):1628-1638.

22. Hoehn D, Miranda RN, Kanagal-Shamanna R, Lin P, Medeiros LJ. Splenic B-cell lymphomas with more than 55% prolymphocytes in blood: evidence for prolymphocytoid transformation. *Hum Pathol*. 2012;43(11):1828-1838.
23. Klapproth K, Wirth T. Advances in the understanding of MYC-induced lymphomagenesis. *Br J Haematol*. 2010;149(4):484-497.
24. Lens D, Coignet LJ, Brito-Babapulle V, et al. B cell prolymphocytic leukaemia (B-PLL) with complex karyotype and concurrent abnormalities of the p53 and c-MYC gene. *Leukemia*. 1999;13(6):873-876.
25. Merchant S, Schlette E, Sanger W, Lai R, Medeiros LJ. Mature B-cell leukemias with more than 55% prolymphocytes: report of 2 cases with Burkitt lymphoma-type chromosomal translocations involving c-myc. *Arch Pathol Lab Med*. 2003;127(3):305-309.
26. Kuriakose P, Perveen N, Maeda K, Wiktor A, Van Dyke DL. Translocation (8;14)(q24;q32) as the sole cytogenetic abnormality in B-cell prolymphocytic leukemia. *Cancer Genet Cytogenet*. 2004;150(2):156-158.
27. Crisostomo RH, Fernandez JA, Caceres W. Complex karyotype including chromosomal translocation (8;14) (q24;q32) in one case with B-cell prolymphocytic leukemia. *Leuk Res*. 2007;31(5):699-701.
28. Put N, Van Roosbroeck K, Konings P, et al; BCGHo and the GFCH. Chronic lymphocytic leukemia and prolymphocytic leukemia with MYC translocations: a subgroup with an aggressive disease course. *Ann Hematol*. 2012;91(6):863-873.
29. Flatley E, Chen AI, Zhao X, et al. Aberrations of MYC are a common event in B-cell prolymphocytic leukemia. *Am J Clin Pathol*. 2014;142(3):347-354.
30. Hemann MT, Bric A, Teruya-Feldstein J, et al. Evasion of the p53 tumour surveillance network by tumour-derived MYC mutants. *Nature*. 2005;436(7052):807-811.
31. Graham M, Adams JM. Chromosome 8 breakpoint far 3' of the c-myc oncogene in a Burkitt's lymphoma 2;8 variant translocation is equivalent to the murine pvt-1 locus. *EMBO J*. 1986;5(11):2845-2851.
32. Shtivelman E, Henglein B, Groitl P, Lipp M, Bishop JM. Identification of a human transcription unit affected by the variant chromosomal translocations 2;8 and 8;22 of Burkitt lymphoma. *Proc Natl Acad Sci U S A*. 1989;86(9):3257-3260.
33. Cho SW, Xu J, Sun R, et al. Promoter of lncRNA Gene PVT1 is a tumor-suppressor DNA boundary element. *Cell*. 2018;173(6):1398-1412.e1322.
34. Solé F, Woessner S, Espinet B, et al. Cytogenetic abnormalities in three patients with B-cell prolymphocytic leukemia. *Cancer Genet Cytogenet*. 1998;103(1):43-45.
35. Haberl S, Haferlach T, Stengel A, Jeromin S, Kern W, Haferlach C. MYC rearranged B-cell neoplasms: impact of genetics on classification. *Cancer Genet*. 2016;209(10):431-439.
36. Cohen JB, Ruppert AS, Heerema NA, et al. Complex karyotype is associated with aggressive disease and shortened progression-free survival in patients with newly diagnosed mantle cell lymphoma. *Clin Lymphoma Myeloma Leuk*. 2015;15(5):278-285.e271.
37. Sarkozy C, Terré C, Jardin F, et al. Complex karyotype in mantle cell lymphoma is a strong prognostic factor for the time to treatment and overall survival, independent of the MCL international prognostic index. *Genes Chromosomes Cancer*. 2014;53(1):106-116.
38. Salido M, Baró C, Oscier D, et al. Cytogenetic aberrations and their prognostic value in a series of 330 splenic marginal zone B-cell lymphomas: a multicenter study of the Splenic B-Cell Lymphoma Group. *Blood*. 2010;116(9):1479-1488.
39. Sutton L, Chevret S, Tournilhac O, et al; Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC) and Groupe Français d'étude de la Leucémie Lymphoïde Chronique (GFLLC). Autologous stem cell transplantation as a first-line treatment strategy for chronic lymphocytic leukemia: a multicenter, randomized, controlled trial from the SFGM-TC and GFLLC. *Blood*. 2011;117(23):6109-6119.
40. Lepretre S, Aurrant T, Mahé B, et al. Excess mortality after treatment with fludarabine and cyclophosphamide in combination with alemtuzumab in previously untreated patients with chronic lymphocytic leukemia in a randomized phase 3 trial. *Blood*. 2012;119(22):5104-5110.
41. Baliakas P, Iskas M, Gardiner A, et al. Chromosomal translocations and karyotype complexity in chronic lymphocytic leukemia: a systematic reappraisal of classic cytogenetic data. *Am J Hematol*. 2014;89(3):249-255.
42. Baliakas P, Jeromin S, Iskas M, et al; ERIC, the European Research Initiative on CLL. Cytogenetic complexity in chronic lymphocytic leukemia: definitions, associations, and clinical impact. *Blood*. 2019;133(11):1205-1216.
43. Chapiro E, Lesty C, Gabillaud C, et al; Groupe Francophone de Cytogénétique Hématologique (GFCH) and the French Innovative Leukemia Organization (FILO) group. "Double-hit" chronic lymphocytic leukemia: an aggressive subgroup with 17p deletion and 8q24 gain. *Am J Hematol*. 2018;93(3):375-382.
44. Hu Z, Medeiros LJ, Chen Z, et al. Mantle cell lymphoma with MYC rearrangement: a report of 17 patients. *Am J Surg Pathol*. 2017;41(2):216-224.
45. Döhner H, Stilgenbauer S, Benner A, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. *N Engl J Med*. 2000;343(26):1910-1916.
46. Beà S, Valdés-Mas R, Navarro A, et al. Landscape of somatic mutations and clonal evolution in mantle cell lymphoma. *Proc Natl Acad Sci U S A*. 2013;110(45):18250-18255.
47. Rossi D, Trifonov V, Fangazio M, et al. The coding genome of splenic marginal zone lymphoma: activation of NOTCH2 and other pathways regulating marginal zone development. *J Exp Med*. 2012;209(9):1537-1551.
48. Guiéze R, Wu CJ. Genomic and epigenomic heterogeneity in chronic lymphocytic leukemia. *Blood*. 2015;126(4):445-453.
49. Love C, Sun Z, Jima D, et al. The genetic landscape of mutations in Burkitt lymphoma. *Nat Genet*. 2012;44(12):1321-1325.
50. Huynh KD, Fischle W, Verdin E, Bardwell VJ. BCoR, a novel corepressor involved in BCL-6 repression. *Genes Dev*. 2000;14(14):1810-1823.
51. Grossmann V, Tiacci E, Holmes AB, et al. Whole-exome sequencing identifies somatic mutations of BCOR in acute myeloid leukemia with normal karyotype. *Blood*. 2011;118(23):6153-6163.
52. Damm F, Chesnais V, Nagata Y, et al. BCOR and BCORL1 mutations in myelodysplastic syndromes and related disorders. *Blood*. 2013;122(18):3169-3177.
53. Jallades L, Baseggio L, Sujobert P, et al. Exome sequencing identifies recurrent BCOR alterations and the absence of KLF2, TNFAIP3 and MYD88 mutations in splenic diffuse red pulp small B-cell lymphoma. *Haematologica*. 2017;102(10):1758-1766.
54. Lefebure M, Tothill RW, Kruse E, et al. Genomic characterisation of Eµ-Myc mouse lymphomas identifies Bcor as a Myc co-operative tumour-suppressor gene. *Nat Commun*. 2017;8(1):14581.
55. van der Velden VH, Hoogeveen PG, de Ridder D, et al. B-cell prolymphocytic leukemia: a specific subgroup of mantle cell lymphoma. *Blood*. 2014;124(3):412-419.
56. Zhang J, Jima D, Moffitt AB, et al. The genomic landscape of mantle cell lymphoma is related to the epigenetically determined chromatin state of normal B cells. *Blood*. 2014;123(19):2988-2996.
57. Davi F, Maloum K, Michel A, et al. High frequency of somatic mutations in the VH genes expressed in prolymphocytic leukemia. *Blood*. 1996;88(10):3953-3961.
58. Del Giudice I, Davis Z, Matutes E, et al. IgVH genes mutation and usage, ZAP-70 and CD38 expression provide new insights on B-cell prolymphocytic leukemia (B-PLL). *Leukemia*. 2006;20(7):1231-1237.
59. Shvidel L, Shtalrid M, Bassous L, Klepfish A, Vorst E, Berrebi A. B-cell prolymphocytic leukemia: a survey of 35 patients emphasizing heterogeneity, prognostic factors and evidence for a group with an indolent course. *Leuk Lymphoma*. 1999;33(1-2):169-179.
60. Chow KU, Kim SZ, von Neuhoff N, et al. Clinical efficacy of immunochemotherapy with fludarabine, epirubicin and rituximab in the treatment for chronic lymphocytic leukaemia and prolymphocytic leukaemia. *Eur J Haematol*. 2011;87(5):426-433.
61. Bowen AL, Zomas A, Emmett E, Matutes E, Dyer MJ, Catovsky D. Subcutaneous CAM-PATH-1H in fludarabine-resistant/relapsed chronic lymphocytic and B-prolymphocytic leukaemia. *Br J Haematol*. 1997;96(3):617-619.
62. Amorim S, Stathis A, Gleeson M, et al. Bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma: a dose-escalation, open-label, pharmacokinetic, phase 1 study. *Lancet Haematol*. 2016;3(4):e196-e204.